Sun. Sep 27th, 2020

Market and Financial News Aggregator

Gilead nears deal to buy Immunomedics for more than $20 billion: Report

1 min read



A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner, the Wall Street Journal said, citing people familiar with the matter.



Source link

Leave a Reply